

# Can DAPT be discontinued at one month after PCI in high bleeding risk patients presenting with ACS?

Myeong-Ki Hong\*, MD; Yong-Joon Lee, MD

\*Corresponding author: Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, 03722 Yonsei-ro 50-1, Seodaemun-gu, Seoul, Republic of Korea. E-mail: mkhong61@yuhs.ac

The authors' affiliation can be found at the end of this article.

For patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) with aspirin and a P2Y<sub>12</sub> inhibitor is required for preventing ischaemic events, and 12 months of DAPT is currently the standard treatment<sup>1,2</sup>. However, maintaining DAPT long term may be associated with an increased risk of bleeding, and therefore, the strategy of shortening the duration of DAPT has been investigated<sup>3</sup>. Attaining optimal protection against ischaemic events while avoiding an increase in bleeding-related harm is crucial, especially in patients with high bleeding risk (HBR)<sup>3</sup>. The MASTER DAPT trial randomised HBR patients undergoing PCI and compared 1-month DAPT with ≥3-month DAPT<sup>4</sup>. In accordance with the main trial results, its prespecified, stratified subgroup analysis focusing on patients with an acute or recent myocardial infarction demonstrated that while the risk of cardiovascular events did not differ between the two groups, 1-month DAPT was associated with a reduced risk for Bleeding Academic Research Consortium (BARC) type 2-5 bleeding<sup>5</sup>. However, only biodegradable-polymer sirolimus-eluting stents were used, and approximately 75% of patients in the 1-month DAPT group received P2Y<sub>12</sub> inhibitor monotherapy as a single antiplatelet therapy regimen after DAPT<sup>5</sup>. Therefore, more evidence with different stent types and an alternative single antiplatelet therapy regimen (i.e., aspirin) have been required to support the feasibility of a 1-month DAPT strategy in HBR patients presenting with ACS.

In this issue of EuroIntervention, Cao et al sought to compare the impact of 1-month DAPT versus 3-month DAPT on 1-year ischaemic and bleeding events in HBR patients undergoing PCI for non-ST-segment elevation ACS, based on data from the XIENCE Short DAPT programme<sup>6</sup>. The XIENCE Short DAPT programme consisted of three prospective, multicentre

registries conducted in North America, Europe, and Asia, which represent real-world registries involving various races<sup>6</sup>. This study included 1,164 HBR patients undergoing PCI for non-ST-segment elevation ACS<sup>6</sup>. While the risk of the primary endpoint of death or myocardial infarction was not different between the 1-month DAPT and 3-month DAPT groups, the key secondary endpoint of BARC type 2-5 bleeding was significantly lower in the 1-month DAPT group<sup>6</sup>. In contrast with the MASTER DAPT trial, in this study, biocompatible-polymer everolimus-eluting stents were used, and all patients received aspirin as a single antiplatelet therapy regimen after DAPT<sup>6</sup>. The results of this study further support the feasibility of a 1-month DAPT strategy in HBR patients presenting with ACS, regardless of stent type or single antiplatelet therapy regimen after DAPT. Although these results are outstanding, there are some important aspects to consider while interpreting them. First, this study was not randomised. For instance, radial access was more commonly used in the 1-month DAPT group, which may have contributed to the difference in bleeding events. Second, patients with complex coronary lesions or ST-segment elevation myocardial infarction were excluded. Third, the risk of major bleeding (BARC type 3-5) was not different between the two groups, which may imply that the difference in the bleeding events could be attributed to BARC type 2 bleeding. Moreover, when patients on oral anticoagulation were excluded, BARC type 2-5 bleeding did not differ between the two groups. Lastly, the definitions for HBR were not identical to those proposed by the Academic Research Consortium consensus<sup>7</sup>.

Article, see page e630

To conclude, Cao et al provided important, essential evidence to further support the feasibility of a shortened DAPT – of 1 month – in HBR patients undergoing PCI for ACS and

should be complimented for their outstanding study which may motivate the implementation of further randomised trials regarding the optimal antiplatelet therapy, especially in ACS patients at high bleeding risk. Future studies should acknowledge that modulation of an antiplatelet therapy includes not only shortening DAPT but also dose reduction and the switching of antiplatelet therapy regimens<sup>3</sup>. They should also take into account consensus recommendations aimed at proposing guidance for clinical trial designs for patients at HBR undergoing PCI<sup>7</sup>. Recently, the results from the ULTIMATE-DAPT Trial, which evaluated the efficacy and safety of a ticagrelor-based 1-month DAPT strategy in patients with ACS, have been reported<sup>8</sup>. Furthermore, there is great anticipation for its subsequent substudy, which will focus on high bleeding risk.

## Authors' affiliation

Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

## Conflict of interest statement

M. Hong has received speaker fees from Medtronic and Edwards Lifesciences. Y. Lee has no conflicts of interest to declare.

## References

1. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J*. 2023;44:3720-826.
2. Writing Committee Members; Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2022;79:e21-129.
3. Capodanno D, Mehran R, Krucoff MW, Baber U, Bhatt DL, Capranzano P, Collet JP, Cuisset T, De Luca G, De Luca L, Farb A, Franchi F, Gibson CM, Hahn JY, Hong MK, James S, Kastrati A, Kimura T, Lemos PA, Lopes RD, Magee A, Matsumura R, Mochizuki S, O'Donoghue ML, Pereira NL, Rao SV, Rollini F, Shirai Y, Sibbing D, Smits PC, Steg PG, Storey RF, Ten Berg J, Valgimigli M, Vranckx P, Watanabe H, Windecker S, Serruys PW, Yeh RW, Morice MC, Angiolillo DJ. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium. *Circulation*. 2023;147:1933-44.
4. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stanković G, Iñiguez A, Schultz C, Kornowski R, Ong P, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits PC; MASTER DAPT Investigators. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. *N Engl J Med*. 2021;385:1643-55.
5. Smits PC, Frigoli E, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iñiguez A, Schultz C, Kornowski R, Ong P, Alasnag M, Rodriguez AE, Paradies V, Kala P, Kedev S, Al Mafragi A, Dewilde W, Heg D, Valgimigli M; MASTER DAPT Investigators. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. *J Am Coll Cardiol*. 2022;80:1220-37.
6. Cao D, Vranckx P, Valgimigli M, Sartori S, Angiolillo DJ, Bangalore S, Bhatt DL, Feng Y, Ge J, Hermiller J, Makkar RR, Neumann F, Saito S, Picon H, Toelg R, Maksoud A, Chehab BM, Choi JW, Campo G, de la Torre Hernández JM, Krucoff MW, Kunadian V, Sardella G, Spirito A, Thiele H, Varenne O, Vogel B, Zhou Y, Windecker S, Mehran R. One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes. *EuroIntervention*. 2024;20:e630-42.
7. Capodanno D, Morice MC, Angiolillo DJ, Bhatt DL, Byrne RA, Collieran R, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock SJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhovel U, Krucoff MW, Urban P, Mehran R. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. *J Am Coll Cardiol*. 2020;76:1468-83.
8. Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohyidin BS, Gao F, Shao Y, Wang Y, Zeng H, Li F, Khan HS, Mengal N, Cong H, Wang M, Chen L, Wei Y, Chen F, Stone GW, Chen SL; ULTIMATE-DAPT investigators. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. *Lancet*. 2024 Apr 5. [Epub ahead of print].